Advertisement


Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement



Dec
06
Today In Oncology
Lu-177 Vipivotide Tetraxetan Shows Benefit in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Avoidance of Surgery in Patients With Invasive Breast Cancer and Exceptional Response to Neoadjuvant Systemic Therapy
Adjuvant Pembrolizumab May Improve Quality of Life in Patients With High-Risk Resected Melanoma
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
DNA Repair Protein MRE11 Expression and Disease-Specific Mortality Among Patients With Muscle-Invasive Bladder Cancer Receiving Trimodality Therapy
View More 
Advertisement
© 2022 HSP News Service, L.L.C.
Designed by Harborside